Natera, Inc. $NTRA Stock: Teamwork Financial Advisors LLC Reduces Stake

Teamwork Financial Advisors LLC cut its holdings in Natera, Inc. (NASDAQ:NTRA) by 90.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,028 shares of the medical research company’s stock after selling 9,787 shares during the quarter. Teamwork Financial Advisors LLC’s holdings in Natera were worth $425,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc raised its stake in Natera by 4.6% during the third quarter. Versant Capital Management Inc now owns 815 shares of the medical research company’s stock worth $337,000 after acquiring an additional 36 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after acquiring an additional 47 shares during the last quarter. Raiffeisen Bank International AG boosted its stake in shares of Natera by 48.5% in the 2nd quarter. Raiffeisen Bank International AG now owns 150 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 49 shares in the last quarter. First Horizon Corp boosted its stake in shares of Natera by 5.5% in the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 51 shares in the last quarter. Finally, Purus Wealth Management LLC grew its holdings in shares of Natera by 5.3% during the 3rd quarter. Purus Wealth Management LLC now owns 1,135 shares of the medical research company’s stock valued at $469,000 after purchasing an additional 57 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Barclays raised their target price on shares of Natera from $340.00 to $475.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Citigroup boosted their target price on shares of Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a research note on Tuesday, October 6th. Stephens upped their price target on shares of Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Finally, UBS Group increased their price target on Natera from $290.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $374.64.

Insider Buying and Selling

In related news, CEO Steven Chapman sold 3,580 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $254.07, for a total value of $909,570.60. Following the transaction, the chief executive officer directly owned 102,973 shares of the company’s stock, valued at approximately $26,162,350.11. This represents a 3.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 6,517 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the sale, the insider owned 197,257 shares of the company’s stock, valued at $63,424,043.21. This trade represents a 3.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 52,985 shares of company stock valued at $16,119,137 over the last quarter. Company insiders own 5.05% of the company’s stock.

Natera Trading Up 1.5%

NTRA stock traded up $5.98 during trading on Monday, hitting $399.42. The company had a trading volume of 1,328,970 shares, compared to its average volume of 1,401,286. The stock has a market cap of $57.57 billion, a PE ratio of -293.69 and a beta of 1.50. The business has a 50-day moving average of $358.21 and a 200-day moving average of $275.88. Natera, Inc. has a one year low of $181.00 and a one year high of $437.41.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm’s revenue was up 37.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.74) EPS. Research analysts forecast that Natera, Inc. will post -1.05 EPS for the current year.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.